ALG1L Activators
ALG1L, also known as ALG1 Like, Chitobiase Biogenesis Protein, is a protein that plays a role in the process of N-linked glycosylation, an essential biochemical pathway in eukaryotic cells. It is encoded by the gene ALG1L. This protein is thought to be involved in the early steps of the glycosylation pathway, which is critical for the proper folding, stability, and function of many proteins.
N-linked glycosylation starts in the endoplasmic reticulum (ER) where a precursor oligosaccharide is assembled on a lipid carrier molecule. This precursor is then transferred to nascent proteins, where it is further processed to form complex sugar structures. ALG1L is believed to participate in one of the initial stages of this oligosaccharide assembly, although its exact role is not as well characterized as that of ALG1, another protein in the same pathway.The process of N-linked glycosylation is highly conserved and essential for cell viability. It plays a key role in cell-cell interactions, signaling, and immune recognition. Defects in glycosylation can lead to a group of disorders collectively known as congenital disorders of glycosylation (CDG), which can impact multiple systems in the body.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine is an inhibitor of alpha-mannosidase II, an enzyme involved in glycoprotein processing. By inhibiting this enzyme, swainsonine may indirectly affect N-linked glycosylation processes, potentially influencing the activity or efficacy of proteins like ALG1L. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a potent inhibitor of mannosidase I, an enzyme involved in the N-linked glycosylation pathway. Its inhibition can lead to alterations in glycoprotein processing, which may indirectly impact the function of proteins involved in this pathway, such as ALG1L. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxymannojirimycin is an inhibitor of α-mannosidase, which is involved in glycoprotein processing. Its inhibition can indirectly affect the N-linked glycosylation process, potentially influencing proteins involved in this pathway, including ALG1L. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is a glucosidase inhibitor that may indirectly influence the N-linked glycosylation pathway by affecting glycoprotein processing. This alteration could potentially impact proteins like ALG1L that are involved in glycosylation. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Celgosivir is an α-glucosidase I inhibitor, which could indirectly influence the N-linked glycosylation pathway. This may affect the activity of proteins involved in glycosylation, such as ALG1L. | ||||||
Voglibose | 83480-29-9 | sc-204384 sc-204384A | 10 mg 50 mg | $198.00 $681.00 | ||
Voglibose is an alpha-glucosidase inhibitor, primarily used for diabetes management. Its role in inhibiting glucosidases could indirectly influence glycosylation processes, potentially impacting proteins like ALG1L. | | ||||||
Acarbose | 56180-94-0 | sc-203492 sc-203492A | 1 g 5 g | $226.00 $605.00 | 1 | |
Acarbose is another alpha-glucosidase inhibitor. By influencing glucosidases, it could indirectly affect the N-linked glycosylation pathway, thereby potentially impacting the activity or function of ALG1L. | ||||||